These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16197343)

  • 1. Alicaforsen therapy in inflammatory bowel disease.
    Barish CF
    Expert Opin Biol Ther; 2005 Oct; 5(10):1387-91. PubMed ID: 16197343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT; Sitaraman S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
    Yacyshyn BR; Barish C; Goff J; Dalke D; Gaspari M; Yu R; Tami J; Dorr FA; Sewell KL
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
    Yacyshyn B; Chey WY; Wedel MK; Yu RZ; Paul D; Chuang E
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
    Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
    Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ISIS 2302. Oligo-TCS.
    Drugs R D; 1999 Mar; 1(3):265-7. PubMed ID: 10566042
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis.
    Siegmund B; Zeitz M
    Rocz Akad Med Bialymst; 2004; 49():22-30. PubMed ID: 15631310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
    van Deventer SJ; Tami JA; Wedel MK
    Gut; 2004 Nov; 53(11):1646-51. PubMed ID: 15479686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiadhesion molecule therapy in inflammatory bowel disease.
    van Assche G; Rutgeerts P
    Inflamm Bowel Dis; 2002 Jul; 8(4):291-300. PubMed ID: 12131614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technology evaluation: alicaforsen (Isis).
    Gewirtz AT; Sitaraman SV
    Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1.
    Reinisch W; Hung K; Hassan-Zahraee M; Cataldi F
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S669-S677. PubMed ID: 29757363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
    Panés J; Salas A
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.
    Yacyshyn BR; Schievella A; Sewell KL; Tami JA
    Clin Exp Immunol; 2005 Jul; 141(1):141-7. PubMed ID: 15958080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotide treatment of inflammatory bowel diseases.
    Yacyshyn BR
    Methods Mol Med; 2005; 106():295-305. PubMed ID: 15375323
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of biologic therapy.
    Blonski W; Lichtenstein GR
    Inflamm Bowel Dis; 2007 Jun; 13(6):769-96. PubMed ID: 17304581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alicaforsen for the treatment of inflammatory bowel disease.
    Jairath V; Khanna R; Feagan BG
    Expert Opin Investig Drugs; 2017 Aug; 26(8):991-997. PubMed ID: 28670932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD.
    Philpott JR; Miner PB
    Expert Opin Biol Ther; 2008 Oct; 8(10):1627-32. PubMed ID: 18774928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
    Miner PB; Geary RS; Matson J; Chuang E; Xia S; Baker BF; Wedel MK
    Aliment Pharmacol Ther; 2006 May; 23(10):1427-34. PubMed ID: 16669957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.